CTI BioPharma Corp. (CTIC) Report Analysis
Corporate Events
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 3000 Growth Index
2022-06-24 00:00:00
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 3000 Growth Index
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 2000 Index
2022-06-24 00:00:00
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 2000 Index
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 2000 Growth Index
2022-06-24 00:00:00
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 2000 Growth Index
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell Small Cap Comp Growth Index
2022-06-24 00:00:00
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell Small Cap Comp Growth Index
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 3000 Value Index
2022-06-24 00:00:00
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 3000 Value Index
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 3000 Index
2022-06-24 00:00:00
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 3000 Index
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell Small Cap Completeness Index
2022-06-24 00:00:00
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell Small Cap Completeness Index
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 2500 Value Index
2022-06-24 00:00:00
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 2500 Value Index
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 2500 Index
2022-06-24 00:00:00
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 2500 Index
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell Small Cap Comp Value Index
2022-06-24 00:00:00
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell Small Cap Comp Value Index
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 2000 Value Index
2022-06-24 00:00:00
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 2000 Value Index
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 3000E Value Index
2022-06-24 00:00:00
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 3000E Value Index
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 3000E Growth Index
2022-06-24 00:00:00
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 3000E Growth Index
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 2000 Dynamic Index
2022-06-24 00:00:00
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 2000 Dynamic Index
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 3000E Index
2022-06-24 00:00:00
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 3000E Index
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 2500 Growth Index
2022-06-24 00:00:00
CTI BioPharma Corp.(NasdaqCM:CTIC) added to Russell 2500 Growth Index
CTI BioPharma Corp. has filed a Shelf Registration in the amount of $60.772525 million.
2022-06-16 00:00:00
CTI BioPharma Corp. has filed a Shelf Registration in the amount of $60.772525 million. Security Name: Common Stock Securities Offered: 10,532,500 Transaction Features: ESOP Related Offering
CTI BioPharma Corp.(NasdaqCM:CTIC) added to S&P Biotechnology Select Industry Index
2022-06-11 00:00:00
CTI BioPharma Corp.(NasdaqCM:CTIC) added to S&P Biotechnology Select Industry Index
CTI BioPharma Corp. Presents at 2022 Jefferies Global Healthcare Conference, Jun-10-2022 10:00 AM
2022-06-06 23:03:00
CTI BioPharma Corp. Presents at 2022 Jefferies Global Healthcare Conference, Jun-10-2022 10:00 AM. Venue: Marriott Marquis, New York City, New York, United States.
CTI BioPharma Corp. Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 11:00 AM
2022-05-09 14:47:00
CTI BioPharma Corp. Presents at The JMP Securities Life Sciences Conference 2022, Jun-15-2022 11:00 AM. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States.
CTI BioPharma Corp., Q1 2022 Earnings Call, May 12, 2022
2022-04-28 20:05:00
CTI BioPharma Corp., Q1 2022 Earnings Call, May 12, 2022
CTI BioPharma Corp. to Report Q1, 2022 Results on May 12, 2022
2022-04-28 20:05:00
CTI BioPharma Corp. announced that they will report Q1, 2022 results After-Market on May 12, 2022
CTI BioPharma Corp., Annual General Meeting, Jun 01, 2022
2022-04-19 21:19:00
CTI BioPharma Corp., Annual General Meeting, Jun 01, 2022, at 10:00 Pacific Standard Time. Agenda: To consider election of seven directors; to consider equity incentive plan amendment to increase the share reserve; to consider employee stock purchase plan amendment to increase the share reserve; to consider auditor ratification; and to consider say-on-pay vote.
CTI BioPharma Corp. - Shareholder/Analyst Call
2022-04-19 21:19:00
Annual General Meeting
National Comprehensive Cancer Network Recommends CTI BioPharma Corp.'s VONJO™ (pacritinib) for the Treatment of Myeloproliferative Neoplasms
2022-04-14 11:00:00
CTI BioPharma Corp. announced that VONJO™ (pacritinib), its novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1, has been included as a recommended treatment in the latest National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Myeloproliferative Neoplasms.Pacritinib is an oral kinase inhibitor with activity against wild type Janus Associated Kinase 2 (JAK2), mutant JAK2V617F form and FMS-like tyrosine kinase 3 (FLT3), which contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Myelofibrosis is often associated with dysregulated JAK2 signaling. Pacritinib has higher inhibitory activity for JAK2 over other family members, JAK3 and TYK2. At clinically relevant concentrations, pacritinib does not inhibit JAK1. Pacritinib exhibits inhibitory activity against additional cellular kinases (such as CSF1R and IRAK1), the clinical relevance of which is unknown. VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Important VONJO Safety Information - Hemorrhage: Serious (11%) and fatal (2%) hemorrhages have occurred in VONJO-treated patients with platelet counts <100 × 109/L. Serious (13%) and fatal (2%) hemorrhages have occurred in VONJO-treated patients with platelet counts <50 × 109/L. Grade =3 bleeding events (defined as requiring transfusion or invasive intervention) occurred in 15% of patients treated with VONJO compared to 7% of patients treated on the control arm. Due to hemorrhage, VONJO dose-reductions, dose interruptions, or permanent discontinuations occurred in 3%, 3%, and 5% of patients, respectively. Avoid use of VONJO in patients with active bleeding and hold VONJO 7 days prior to any planned surgical or invasive procedures. Assess platelet counts periodically, as clinically indicated. Manage hemorrhage using treatment interruption and medical intervention. Diarrhea: VONJO causes diarrhea in approximately 48% of patients compared to 15% of patients treated on the control arm. The median time to resolution in VONJO-treated patients was 2 weeks. The incidence of reported diarrhea decreased over time with 41% of patients reporting diarrhea in the first 8 weeks of treatment, 15% in Weeks 8 through 16, and 8% in Weeks 16 through 24. Diarrhea resulted in treatment interruption in 3% of VONJO-treated patients. None of the VONJO-treated patients reported diarrhea that resulted in treatment discontinuation. Serious diarrhea adverse reactions occurred in 2% of patients treated with VONJO compared to no such adverse reactions in patients in the control arm. Control pre-existing diarrhea before starting VONJO treatment. Manage diarrhea with antidiarrheal medications, fluid replacement, and dose-modification. Treat diarrhea with anti–diarrheal medications promptly at the first onset of symptoms. Interrupt or reduce VONJO dose in patients with significant diarrhea despite optimal supportive care. Thrombocytopenia: VONJO can cause worsening thrombocytopenia. VONJO dosing was reduced due to worsening thrombocytopenia in 2% of patients with pre–existing moderate to severe thrombocytopenia (platelet count <100 × 109/L). VONJO dosing was reduced due to worsening thrombocytopenia in 2% of patients with pre–existing severe thrombocytopenia (platelet count <50 × 109/L). Monitor platelet count prior to VONJO treatment and as clinically indicated during treatment. Interrupt VONJO in patients with clinically significant worsening of thrombocytopenia that lasts for more than 7 days. Restart VONJO at 50% of the last given dose once the toxicity has resolved. If toxicity recurs hold VONJO. Restart VONJO at 50% of the last given dose once the toxicity has resolved. Prolonged QT interval: VONJO can cause prolongation of the QTc interval. QTc prolongation of >500 msec was higher in VONJO-treated patients than in patients in the control arm (1.4% vs 1%). QTc increase from baseline by 60 msec or higher was greater in VONJO-treated patients than in control arm patients (1.9% vs 1%). Adverse reactions of QTc prolongation were reported for 3.8% of VONJO-treated patients and 2% of control arm patients. No cases of torsades de pointes were reported. Avoid use of VONJO in patients with a baseline QTc of >480 msec. Avoid use of drugs with significant potential for QTc prolongation in combination with VONJO. Correct hypokalemia prior to and during VONJO treatment. Manage QTc prolongation using VONJO interruption and electrolyte management. Major Adverse Cardiac Events (MACE): Another Janus associated kinase (JAK)-inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which VONJO is not indicated. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with VONJO particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. Thrombosis: Another JAK-inhibitor has increased the risk of thrombosis, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which VONJO is not indicated. Patients with symptoms of thrombosis should be promptly evaluated and treated appropriately. Secondary Malignancies: Another JAK-inhibitor has increased the risk of lymphoma and other malignancies excluding non-melanoma skin cancer (NMSC) (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which VONJO is not indicated. Patients who are current or past smokers are at additional increased risk. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with VONJO, particularly in patients with a known malignancy (other than a successfully treated NMSC), patients who develop a malignancy, and patients who are current or past smokers. Risk of Infection: Another JAK-inhibitor has increased the risk of serious infections (compared to best available therapy) in patients with myeloproliferative neoplasms. Serious bacterial, mycobacterial, fungal and viral infections may occur in patients treated with VONJO.
CTI BioPharma Corp. Presents at Needham 21st Annual Healthcare Conference, Apr-13-2022 01:30 PM
2022-04-06 20:05:00
CTI BioPharma Corp. Presents at Needham 21st Annual Healthcare Conference, Apr-13-2022 01:30 PM.
CTI BioPharma Corp. Contemplates Bankruptcy
2022-03-31 00:00:00
CTI BioPharma Corp. is contemplating filing for bankruptcy, as of March 31, 2022. According to SEC filing, Company said that it is need to raise additional funds to operate business, but additional funds may not be available on acceptable terms, or at all. Any inability to raise required capital when needed could harm its liquidity, financial condition, business, operating results and prospects. If the Company fails to obtain additional capital when needed, it may be required to delay, scale back or eliminate some or all of its research and development programs, reduce selling, general and administrative expenses, be unable to attract and retain highly qualified personnel, refrain from making contractually required payments when due (including debt payments) and/or be forced to cease its operations, liquidate its assets and possibly seek bankruptcy protection.
CTI BioPharma Corp. Auditor Raises 'Going Concern' Doubt
2022-03-31 00:00:00
CTI BioPharma Corp. filed its 10-K on Mar 31, 2022 for the period ending Dec 31, 2021. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Informa plc, Hub and Specialty Pharmacy Models East, Jun 28, 2022 through Jun 30, 2022
2022-03-18 18:56:00
Informa plc, Hub and Specialty Pharmacy Models East, Jun 28, 2022 through Jun 30, 2022. Venue: Parsippany, New Jersey, United States.
CTI BioPharma Corp. Presents at Hub and Specialty Pharmacy Models East, Jun-29-2022 02:00 PM
2022-03-18 18:56:00
CTI BioPharma Corp. Presents at Hub and Specialty Pharmacy Models East, Jun-29-2022 02:00 PM. Venue: Parsippany, New Jersey, United States. Speakers: Melissa Beatty, Director, Patient Services and Reimbursement.
JMP Securities LLC, the JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022
2022-02-16 16:45:00
JMP Securities LLC, The JMP Securities Life Sciences Conference 2022, Jun 15, 2022 through Jun 16, 2022. Venue: Lotte New York Palace, 455 Madison Ave., New York City, New York, United States.
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022
2022-02-14 21:00:00
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.
Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022
2022-02-11 23:04:00
Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.
CTI BioPharma Corp. Announces Extension of FDA Review Period for Pacritinib in Myelofibrosis with Severe Thrombocytopenia
2021-11-30 22:30:00
CTI BioPharma Corp. announced the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for pacritinib for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a baseline platelet count of 9/L. The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to February 28, 2022. In the second quarter of 2021, the FDA granted priority review for CTI's NDA for patients with myelofibrosis with a PDUFA date of November 30, 2021. In the course of product labeling discussions, the FDA requested additional clinical data, which was submitted to the agency on November 24, 2021. The FDA informed the Company that it considers the data submission to constitute a "major amendment" to the NDA and therefore the PDUFA date has been extended by three months to provide additional time for a full review of the submission. At the current time, CTI is not aware of any major deficiencies in the application. Pacritinib is a novel oral kinase inhibitor with specificity for JAK2, IRAK1 and CSF1R, without inhibiting JAK1. The NDA was accepted based on the data from the Phase 3 PERSIST-2 and PERSIST-1 and the Phase 2 PAC203 clinical trials, with a focus on the severely thrombocytopenic (platelet counts less than 50 x 109/L) patients enrolled in these studies who received pacritinib 200 mg twice a day, including both frontline treatment-naive patients and patients with prior exposure to JAK2 inhibitors. In the PERSIST-2 study, in patients with severe thrombocytopenia who were treated with pacritinib 200 mg twice a day, 29% of patients had a reduction in spleen volume of at least 35%, compared to 3% of patients receiving the best available therapy, which included ruxolitinib; 23% of patients had a reduction in total symptom scores of at least 50%, compared to 13% of patients receiving the best available therapy. In the same population of patients treated with pacritinib, adverse events were generally low grade, manageable with supportive care, and rarely led to discontinuation. Platelet counts and hemoglobin levels were also stabilized.
JMP Securities LLC, JMP Securities Hematology & Oncology Summit, Dec 06, 2021 through Dec 07, 2021
2021-10-29 18:02:00
JMP Securities LLC, JMP Securities Hematology & Oncology Summit, Dec 06, 2021 through Dec 07, 2021.
CTI BioPharma Corp. Presents at JMP Securities Hematology & Oncology Summit, Dec-06-2021 03:40 PM
2021-10-29 18:02:00
CTI BioPharma Corp. Presents at JMP Securities Hematology & Oncology Summit, Dec-06-2021 03:40 PM. Speakers: Adam R. Craig, President, CEO, Interim Chief Medical Officer & Director, David H. Kirske, Executive VP, CFO & Secretary.
CTI BioPharma Corp. Announces Topline Data from Final Analysis of the Pre-Vent Clinical Trial Evaluating Pacritinib as A Treatment for Severe Covid-19
2021-10-01 20:05:00
CTI BioPharma Corp. announced topline results from the PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind, placebo-controlled multicenter study, compared pacritinib/standard of care versus placebo/standard of care in hospitalized patients with severe COVID-19, including patients with and without cancer. The primary endpoint of the trial was the proportion of patients who progressed to invasive mechanical ventilation and/or extracorporeal membrane oxygenation or died by Day 28. The study was recently amended to a Phase 2 design due to the availability of COVID-19 vaccines and an evolving COVID-19 environment. The final PRE-VENT analysis was conducted following the randomization of 200 patients. In patients with severe COVID-19 treated with pacritinib/standard of care, compared to placebo/standard of care, a statistically significant improvement in the primary endpoint of progression to invasive mechanical ventilation and/or extracorporeal membrane oxygenation or death by Day 28 was not demonstrated (26.3% vs. 24.8% [OR: 1.01 (95% CI: 0.51-1.99)], P=0.98). Pacritinib was generally well-tolerated by patients with severe COVID-19, with lower rates of grade 3+ events and serious adverse events being reported in patients treated with pacritinib/standard of care compared to placebo/standard of care (29.2% vs. 40.6% and 20.8% vs. 32.7%, respectively). The most common adverse events comparing pacritinib/standard of care to placebo/standard of care were increased alanine aminotransferase (15.6% vs. 16.8%), anemia (12.5% vs. 17.8%), bradycardia (15.6% vs. 10.9%), constipation (12.5% vs. 12.9%), hypokalemia (12.5% vs. 12.9%), and hyperkalemia (9.4% vs. 10.9%).
CTI Wins $188 Million GSA FEDSIM SBIR Phase III Contract to Provide Multi-Domain Analysis, Evaluation, and Software for Tactical and Remote Operations
2021-09-21 13:07:00
CTI announced it has been awarded a $188 million GSA FEDSIM SBIR Phase III contract: "Multi-Domain Analysis, Evaluation, and Software for Tactical and Remote Operations (MAESTRO)." MAESTRO is a multi-sponsor, combined effort for engineering services and software development to integrate SBIR technologies into existing manned and unmanned vehicles and cloud solutions, leveraging CTI's Small Business Innovative Research (SBIR) developed technology. CTI has developed a range of technologies in the SBIR program, including enhanced and advanced air, ground, and sea mission awareness and control; analysis of "Big Data" from tactical and operational environments for discerning patterns of life, opportunities for exploitation, and awareness of own force vulnerabilities; visualization, understanding, and response to denied and degraded navigation and timing environments; enhanced planning, analysis, and review of manned and unmanned platform missions; and advanced software architectures and approaches for dynamic, flexible, secure applications from the edge of the battlefield to the operations center to the global cloud. The contract provides for a five-year period of performance.
CTI BioPharma Corp.(NasdaqCM:CTIC) added to S&P Global BMI Index
2021-09-20 00:00:00
CTI BioPharma Corp.(NasdaqCM:CTIC) added to S&P Global BMI Index
CTI BioPharma Corp. and DRI Healthcare Trust Announce Up to $135 Million Debt and Royalty Transaction
2021-08-25 11:30:00
CTI BioPharma Corp. announced transactions totaling up to $135 million in funding for CTI, with $50 million in secured debt to be funded at closing and $60 million to purchase a tiered royalty on sales of pacrinitib upon product approval of pacrinitib by the U.S. Food and Drug Administration (FDA). The proceeds of the transactions will be used by CTI to fund the commercialization of pacritinib for the treatment of myelofibrosis patients with severe thrombocytopenia. CTI has a New Drug Application (NDA) under priority review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2021, and is preparing for a potential commercial launch by end of year. DRI Healthcare will provide a $50 million credit facility at closing. The credit facility bears interest at LIBOR + 8.25% (with a LIBOR floor of 1.75%) and is interest-only for the loan term of 5 years, with the outstanding principal due at maturity. The company will be subject to one financial covenant, which is maintaining minimum liquidity of at least $10 million during the term of the loan. DRI Healthcare will also provide CTI with $60 million upon receiving accelerated approval of pactritinib, and will receive royalties on annual pacrinitib net sales in the United States of 9.6% for the first $125 million of annual U.S. net sales, 4.5% between $125 million and $175 million of annual U.S. net sales, 0.5% between $175 million and $400 million of annual U.S. net sales, with no entitlement above $400 million of annual U.S. net sales. CTI will be entitled up to an additional $25 million on achievement of certain sales milestones.
CTI BioPharma Corp. Announces Appointment of Diane Parks to Its Board of Directors
2021-08-24 11:00:00
CTI BioPharma Corp. announced the appointment of Diane Parks to its Board of Directors. Ms. Parks has overseen the launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Amgen, and Genentech. Throughout Ms. Parks' biopharma industry career spanning more than three decades, she has held a variety of commercial leadership positions. As Senior Vice President, Head of U.S. Commercial at Kite Pharma, Ms. Parks led the launch and "go to market" strategic planning and execution for YESCARTA®, the first CAR-T therapy for relapsed or refractory large B-cell lymphoma. As Vice President, Head of Global Marketing at Pharmacyclics, she oversaw the development and execution of all marketing strategies, as well as data insights to inform commercial decision making, for IMBRUVICA® for the treatment of Waldenstrom's macroglobulinemia and chronic lymphocytic leukemia. At Amgen, she led the nephrology and hospital sales teams and launched three products, including for colorectal cancer and idiopathic thrombocytopenia, in the academic hospital market. In a variety of roles at Genentech, including Senior Vice President, Specialty Biotherapeutics and Managed Care, she led sales, marketing, and other commercial operations activities and launched multiple products. Currently, Ms. Parks serves on the Board of Directors of Calliditas Therapeutics AB, Soligenix, TriSalus Life Sciences, Kura Oncology, and the Lymphoma Research Foundation.
CTI BioPharma Corp. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 02:00 PM
2021-08-04 12:33:00
CTI BioPharma Corp. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 02:00 PM. Speakers: Adam R. Craig, President, CEO, Interim Chief Medical Officer & Director, David H. Kirske, Executive VP, CFO & Secretary.
CTI BioPharma Corp. Presents at Lake Street Capital Markets 5th Annual Best Ideas Growth Conference, Sep-14-2021
2021-07-31 04:07:00
CTI BioPharma Corp. Presents at Lake Street Capital Markets 5th Annual Best Ideas Growth Conference, Sep-14-2021 .
Lake Street Capital Markets, LLC, Lake Street Capital Markets 5th Annual Best Ideas Growth Conference, Sep 14, 2021 through Sep 15, 2021
2021-07-30 21:59:00
Lake Street Capital Markets, LLC, Lake Street Capital Markets 5th Annual Best Ideas Growth Conference, Sep 14, 2021 through Sep 15, 2021.
CTI BioPharma Corp., Q2 2021 Earnings Call, Aug 05, 2021
2021-07-29 11:00:00
CTI BioPharma Corp., Q2 2021 Earnings Call, Aug 05, 2021
CTI BioPharma Corp. to Report Q2, 2021 Results on Aug 05, 2021
2021-07-29 11:00:00
CTI BioPharma Corp. announced that they will report Q2, 2021 results After-Market on Aug 05, 2021
BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021
2021-07-01 10:09:00
BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021.
Fundamental Summary
At a high level, the metrics from CTI BioPharma's Q1 financial report release were demonstrably negative. Their growth, value, and income factors performance indicate that company management are not executing well their business plan. Typically, results like these translate into sustained negative momentum and strong downward pressure on stock price. Correspondingly, CTI BioPharma received a ranking of 50 and a UNDERPERFORM recommendation.
CTI BioPharma reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 37.18 million compared to USD 17.27 million a year ago. Basic loss per share from continuing operations was USD 0.37 compared to USD 0.23 a year ago. Diluted loss per share from continuing operations was USD 0.37 compared to USD 0.23 a year ago.
Business Description
CTI BioPharma, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma in May 2014. CTI BioPharma was incorporated in 1991 and is headquartered in Seattle, Washington.
Sector Overview
CTI BioPharma is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. CTI BioPharma's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | 18,656.7 | 4272.7% | 62 | |
| Net Cashflow | 63.8 | 154.7% | 48 | |
| Capital Expenditure | -0.0 | 0.0% | 74 | |
| Asset Turnover | 0.0 | 0.0% | 67 | |
| Free Cashflow | -1.0 | -8.5% | 60 |
* All values are TTM
The below chart reflects CTI BioPharma's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While CTI BioPharma's peer average final assessment score stands on 68.0, CTI BioPharma's score is 50.
- CTIC
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. CTI BioPharma's stock is now priced above its 50-day and 200-day, but below its 5-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium and long-term. In particular, many institutional investors keep close watch of the 200-day moving average. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), CTI BioPharma's stock indicates that it's likely oversold. Overall, these technical indicators signal positive upward momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 73.
5D MA
5.79
50D MA
5.19
200D MA
3.45
MACD
0.18
RSI
10.56
STOCH
34.23
Balance Sheet Analysis
CTI BioPharma's most recent balance sheet report was not encouraging. CTI BioPharma's price to book ratio (P/B) was reported as -21.4 and represents -132.6% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. Their book value factor metrics are even more concerning when compared to their peers. Consequently, their book value factors movement received a grade of 37. Also, CTI BioPharma published concerning equity metrics for this filing. In the current report, equity stood at -27.9, which represents a -841.1% change from the last report. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. This performance is significantly less impressive than its peers and competitors. Consequently, their equity movement received a grade of 37. On the other hand, Cash & Equivalents, jumped out as looking rather positive. CTI BioPharma reported a positive trendline in their cash and cash equivalents metrics. Specifically, they reported that cash and cash equivalents were 96.9, representing 48.1% change from the last report. Its impressive cash and cash equivalents metrics should support upward pressure on its's stock price. Consequently, their cash and cash equivalents movement received a grade of 92. Because of these weaknesses, their balance sheet received an overall score of 54.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 131.4 | 81.5% | 70 |
| Liabilities | 159.4 | 132.1% | 84 |
| Price to Book | -21.4 | -132.6% | 37 |
| Cash & Equivalents | 96.9 | 48.1% | 92 |
| Equity | -27.9 | -841.1% | 37 |
The below chart describes CTI BioPharma's performance as reflected on its balance sheet with respect to its peers. While CTI BioPharma received a balance sheet score of 54, the average of its peers stands on 66.0.
- CTIC
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 0 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 1 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 2 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 3 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 4 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 5 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 6 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 7 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 8 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 9 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 10 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 11 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 12 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 13 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 14 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 15 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 16 | 1 |
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 17 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 18 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 19 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 20 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 21 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 22 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 23 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 24 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 26 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 27 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 28 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 29 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 30 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 31 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 32 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 33 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 34 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 35 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 36 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 37 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 38 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 39 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 40 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 41 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 42 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 43 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 44 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 45 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 46 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 47 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 48 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 49 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 50 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 51 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 53 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 54 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 55 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 56 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 57 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 58 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 59 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 60 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 61 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 62 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 63 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 64 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 65 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 66 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 67 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 68 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 69 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 70 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 72 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 73 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 74 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 75 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 76 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 77 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 79 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 80 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 81 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 82 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 83 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 84 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 85 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 86 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 87 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 88 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
A few key income statement metrics in this report were discouraging. CTI BioPharma reported concerning EBITDA this period. At filing, EBITDA was reported as -112.2, representing -19.0% change from the previous period. This metric might have a 24.4 percent impact on companies in the same industry and with the same market capitalization. Their EBITDA metrics are even more problematic when compared to their peers. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their EBITDA a grade of 50. Also, Return factors metrics and ratios were disappointing in this report. CTI BioPharma reported a return on equity (ROE) ratio of 18656.7, representing a change of 4272.7% from the last report.change of 4272.7% from the previous period. This metric might have a 3.6 percent impact on companies in the same industry and with the same market capitalization. The company's return factor metrics return on equity and return on assets are even more concerning when compared to their peers. Consequently, their return factors received a grade of 62. That said, one metric, Revenue Efficiency, stood out as strongly positive. CTI BioPharma did an excellent job managing its revenue efficiency this past period. CTI BioPharma's revenue efficiency is 2.3 according to the metrics in the current filing, which represents a 0.0% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 13.1%. Their impressive revenue efficiency is even more impressive relative to its peers and competitors in the current market. As a result, its revenue efficiency earned a score of 84. Consequently, the companie's income statement earned a rank of 59.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | -112.2 | -19.0% | 50 |
| Total Revenues | 2.3 | 0.0% | 84 |
| Return on Equity | 18,656.7 | 4272.7% | 62 |
The below chart describes CTI BioPharma's performance as reflected on its income statement with respect to its peers. While CTI BioPharma received a income statement score of 59 , the average of its peers stands on 71.0.
- CTIC
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 0 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 1 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 2 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 3 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 4 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 5 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 6 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 7 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 8 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 9 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 10 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 11 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 12 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 13 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 14 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 15 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 16 | 1 |
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 17 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 18 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 19 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 20 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 21 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 22 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 23 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 24 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 26 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 27 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 28 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 29 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 30 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 31 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 32 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 33 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 34 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 35 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 36 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 37 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 38 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 39 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 40 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 41 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 42 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 43 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 44 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 45 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 46 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 47 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 48 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 49 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 50 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 51 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 53 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 54 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 55 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 56 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 57 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 58 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 59 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 60 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 61 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 62 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 63 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 64 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 65 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 66 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 67 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 68 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 69 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 70 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 72 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 73 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 74 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 75 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 76 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 77 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 79 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 80 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 81 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 82 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 83 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 84 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 85 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 86 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 87 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 88 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Results from CTI BioPharma's current financials were concerning, in two areas in particular: Net Cash Flow and Free Cash flow. CTI BioPharma's net cash flow metrics were 63.8 according to their current filing, which represents a 154.7% change from the previous report. Their net cash flow momentum should be a cause for concern and could bring negative momentum for CTI BioPharma's stock price going forward. Consequently, their net cash flow movement received a grade of 48. Also, Free cash flow numbers published by CTI BioPharma were -1.0, which was a -8.5% change from the previous filing. Companies in the same sector and market capitalization will usually be affected by up to 2.6 percent by this parameter. These free cash flow numbers show that management has not been executing well in generating critical cash flow while also encouraging growth. Consequently, their free cash flow movement received a grade of 60. At the same time, one {cash_flow} metric, Capex, was actually strongly positive. CTI BioPharma's published capital expenditures (CapEx) numbers were encouraging and reflected management's balanced change strategy. CTI BioPharma recorded CapEx of -0.0, which represents 0.0% change from the previous report. This performance is all the more impressive relative to their peers and competitors. The company's CapEx movement, therefore, received a grade of 74. The company's cash flow, Therefore, earned a score of 56.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | 63.8 | 154.7% | 48 |
| Capital Expenditure | -0.0 | 0.0% | 74 |
| Asset Turnover | 0.0 | 0.0% | 67 |
| Free Cashflow | -1.0 | -8.5% | 60 |
The below chart describes CTI BioPharma's performance as reflected on its cash flow with respect to its peers. While CTI BioPharma received a cash flow score of 56, the average of its peers stands on 70.0.
- CTIC
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 0 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 1 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 2 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 3 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 4 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 5 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 6 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 7 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 8 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 9 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 10 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 11 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 12 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 13 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 14 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 15 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 16 | 1 |
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 17 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 18 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 19 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 20 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 21 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 22 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 23 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 24 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 26 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 27 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 28 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 29 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 30 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 31 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 32 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 33 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 34 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 35 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 36 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 37 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 38 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 39 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 40 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 41 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 42 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 43 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 44 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 45 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 46 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 47 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 48 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 49 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 50 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 51 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 53 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 54 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 55 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 56 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 57 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 58 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 59 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 60 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 61 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 62 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 63 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 64 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 65 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 66 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 67 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 68 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 69 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 70 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 72 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 73 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 74 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 75 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 76 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 77 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 79 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 80 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 81 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 82 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 83 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 84 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 85 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 86 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 87 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 88 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.